|
Published by: Global Markets Direct
Published: Sep. 25, 2012 - 53 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Rhino-Conjunctivitis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Rhino-Conjunctivitis
- Rhino-Conjunctivitis Therapeutics under Development by Companies
- Rhino-Conjunctivitis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Rhino-Conjunctivitis Therapeutics – Products under Development by Companies
- Rhino-Conjunctivitis Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Rhino-Conjunctivitis Therapeutics Development
- ALK-Abello A/S
- Stallergenes S.A.
- Cytos Biotechnology AG
- Allergopharma Joachim Ganzer KG
- Laboratorios LETI S.L.
- Rhino-Conjunctivitis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- CYT-003-QbG10 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- rBet v1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Olea Europaea Pollen Extract - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Modified Allergen Extract - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MK-7243 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AL-0704rP - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Mutaflor - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MK-3641 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Depigoid Birch - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- gpASIT + TM - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ALK Birch Pollen Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AL-0701rP - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Osiris - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Birch Pollen Allergen - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Rhino-Conjunctivitis Therapeutics – Drug Profile Updates
- Rhino-Conjunctivitis Therapeutics - Dormant Products
- Rhino-Conjunctivitis – Product Development Milestones
- Featured News & Press Releases
- Mar 21, 2012: Paladin Labs Receives Canadian Approval For Oralair
- Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA
- May 24, 2011: Paladin Labs Files New Drug Submission For Oralair
- Apr 18, 2011: ALK To Receive GRAZAX Reimbursement In Denmark
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Rhino-Conjunctivitis, H2 2012
- Products under Development for Rhino-Conjunctivitis – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- ALK-Abello A/S, H2 2012
- Stallergenes S.A., H2 2012
- Cytos Biotechnology AG, H2 2012
- Allergopharma Joachim Ganzer KG, H2 2012
- Laboratorios LETI S.L., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Rhino-Conjunctivitis Therapeutics – Drug Profile Updates
- Rhino-Conjunctivitis Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Rhino-Conjunctivitis, H2 2012
- Products under Development for Rhino-Conjunctivitis – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractRhino-Conjunctivitis – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Rhino-Conjunctivitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhino-Conjunctivitis. Rhino-Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Rhino-Conjunctivitis.
- A review of the Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rhino-Conjunctivitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Rhino-Conjunctivitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
